Valdoxan: Efficacy in moderate to severe depression

Valdoxan is effective whatever the intensity of depressive symptoms. The efficacy of Valdoxan was observed in the more severely depressed patients (baseline HAM-D ≥ 25) in all positive placebo-controlled studies.
Efficacy of Valdoxan in severe depression
Results of the meta-analysis of three positive, randomized, double-blind, placebo controlled studies in 357 patients treated with Valdoxan and 360 patients [...]

Valdoxan: Significant efficacy on core symptoms

Valdoxan provides MDD patients with a significant symptomatic relief, as demonstrated by well-documented improvements in depressed mood, anxiety symptoms, and also sleep-wake disturbances (daytime impairment and sleep disturbances).
Efficacy of Valdoxan on depressed mood
Valdoxan has been demonstrated to be significantly effective in relieving depressed mood of patients with MDD, the most characteristic symptom of depression.
In a [...]

Valdoxan : Significant efficacy in the short term

Valdoxan’s antidepressant efficacy has been demonstrated in a large clinical program including 5 800 patients of whom 3 900 were treated with Valdoxan. The short-term efficacy of Valdoxan has been demonstrated over treatment periods of 6 to 12 weeks using standardized scales (Hamilton Depression Rating Scale [HAMD], Montgomery and Asberg Depression Rating Scale [MADRS], Clinical [...]




Access to this website is intended for the use of Healthcare Professionals only. By clicking the button "I agree" herebelow, you certify being a Healthcare Professional.


Back